Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
Identifieur interne : 002F65 ( PascalFrancis/Corpus ); précédent : 002F64; suivant : 002F66Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
Auteurs : J. S. Schneider ; A. Pope-Coleman ; M. Van Velson ; F. Menzaghi ; G. K. LloydSource :
- Movement disorders [ 0885-3185 ] ; 1998.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 98-0354366 INIST |
---|---|
ET : | Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
AU : | SCHNEIDER (J. S.); POPE-COLEMAN (A.); VAN VELSON (M.); MENZAGHI (F.); LLOYD (G. K.) |
AF : | Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 3 aut.); SIBIA Neurosciences, Inc/La Jolla, California/Etats-Unis (4 aut., 5 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. 4; Pp. 637-642; Bibl. 28 ref. |
LA : | Anglais |
CC : | 002B02B06 |
FD : | Parkinsonisme; Lévodopa; Chimiothérapie; Antiparkinsonien; Agoniste; Récepteur nicotinique; Acétylcholine; Neurone; Association médicamenteuse; Motricité; Psychométrie; Traitement; Dose efficace; Relation dose réponse; Singe; Animal adulte; Mâle; SIB 1508Y |
FG : | Primates; Mammalia; Vertebrata; Système nerveux pathologie; Trouble neurologique |
ED : | Parkinsonism; Levodopa; Chemotherapy; Antiparkinson agent; Agonist; Nicotinic receptor; Acetylcholine; Neuron; Drug combination; Motricity; Psychometrics; Treatment; Effective dose; Dose activity relation; Monkey; Adult animal; Male |
EG : | Primates; Mammalia; Vertebrata; Nervous system diseases; Neurological disorder |
GD : | Aufbereiten |
SD : | Parkinson síndrome; Levodopa; Quimioterapia; Antiparkinsoniano; Agonista; Receptor nicotínico; Acetilcolina; Neurona; Asociación medicamentosa; Motricidad; Psicometría; Tratamiento; Dosis eficaz; Relación dosis respuesta; Mono; Animal adulto; Macho |
LO : | INIST-20953.354000077139450030 |
ID : | 98-0354366 |
Links to Exploration step
Pascal:98-0354366Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, J S" sort="Schneider, J S" uniqKey="Schneider J" first="J. S." last="Schneider">J. S. Schneider</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pope Coleman, A" sort="Pope Coleman, A" uniqKey="Pope Coleman A" first="A." last="Pope-Coleman">A. Pope-Coleman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Velson, M" sort="Van Velson, M" uniqKey="Van Velson M" first="M." last="Van Velson">M. Van Velson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menzaghi, F" sort="Menzaghi, F" uniqKey="Menzaghi F" first="F." last="Menzaghi">F. Menzaghi</name>
<affiliation><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lloyd, G K" sort="Lloyd, G K" uniqKey="Lloyd G" first="G. K." last="Lloyd">G. K. Lloyd</name>
<affiliation><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0354366</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0354366 INIST</idno>
<idno type="RBID">Pascal:98-0354366</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</title>
<author><name sortKey="Schneider, J S" sort="Schneider, J S" uniqKey="Schneider J" first="J. S." last="Schneider">J. S. Schneider</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pope Coleman, A" sort="Pope Coleman, A" uniqKey="Pope Coleman A" first="A." last="Pope-Coleman">A. Pope-Coleman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Velson, M" sort="Van Velson, M" uniqKey="Van Velson M" first="M." last="Van Velson">M. Van Velson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menzaghi, F" sort="Menzaghi, F" uniqKey="Menzaghi F" first="F." last="Menzaghi">F. Menzaghi</name>
<affiliation><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lloyd, G K" sort="Lloyd, G K" uniqKey="Lloyd G" first="G. K." last="Lloyd">G. K. Lloyd</name>
<affiliation><inist:fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylcholine</term>
<term>Adult animal</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dose activity relation</term>
<term>Drug combination</term>
<term>Effective dose</term>
<term>Levodopa</term>
<term>Male</term>
<term>Monkey</term>
<term>Motricity</term>
<term>Neuron</term>
<term>Nicotinic receptor</term>
<term>Parkinsonism</term>
<term>Psychometrics</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Agoniste</term>
<term>Récepteur nicotinique</term>
<term>Acétylcholine</term>
<term>Neurone</term>
<term>Association médicamenteuse</term>
<term>Motricité</term>
<term>Psychométrie</term>
<term>Traitement</term>
<term>Dose efficace</term>
<term>Relation dose réponse</term>
<term>Singe</term>
<term>Animal adulte</term>
<term>Mâle</term>
<term>SIB 1508Y</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHNEIDER (J. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>POPE-COLEMAN (A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VAN VELSON (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MENZAGHI (F.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LLOYD (G. K.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>SIBIA Neurosciences, Inc</s1>
<s2>La Jolla, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>637-642</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000077139450030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0354366</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Agonist</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Agonista</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur nicotinique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Nicotinic receptor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor nicotínico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Acétylcholine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Acetylcholine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Acetilcolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Neurone</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Neuron</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Neurona</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Motricité</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Motricity</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Motricidad</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Psychométrie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Psychometrics</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Psicometría</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Dose efficace</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Effective dose</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Dosis eficaz</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Relation dose réponse</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Dose activity relation</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Relación dosis respuesta</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Singe</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Monkey</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Mono</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Animal adulte</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Adult animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Animal adulto</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Mâle</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Male</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Macho</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>SIB 1508Y</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fN21><s1>236</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 98-0354366 INIST</NO>
<ET>Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys</ET>
<AU>SCHNEIDER (J. S.); POPE-COLEMAN (A.); VAN VELSON (M.); MENZAGHI (F.); LLOYD (G. K.)</AU>
<AF>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 3 aut.); SIBIA Neurosciences, Inc/La Jolla, California/Etats-Unis (4 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. 4; Pp. 637-642; Bibl. 28 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinsonisme; Lévodopa; Chimiothérapie; Antiparkinsonien; Agoniste; Récepteur nicotinique; Acétylcholine; Neurone; Association médicamenteuse; Motricité; Psychométrie; Traitement; Dose efficace; Relation dose réponse; Singe; Animal adulte; Mâle; SIB 1508Y</FD>
<FG>Primates; Mammalia; Vertebrata; Système nerveux pathologie; Trouble neurologique</FG>
<ED>Parkinsonism; Levodopa; Chemotherapy; Antiparkinson agent; Agonist; Nicotinic receptor; Acetylcholine; Neuron; Drug combination; Motricity; Psychometrics; Treatment; Effective dose; Dose activity relation; Monkey; Adult animal; Male</ED>
<EG>Primates; Mammalia; Vertebrata; Nervous system diseases; Neurological disorder</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson síndrome; Levodopa; Quimioterapia; Antiparkinsoniano; Agonista; Receptor nicotínico; Acetilcolina; Neurona; Asociación medicamentosa; Motricidad; Psicometría; Tratamiento; Dosis eficaz; Relación dosis respuesta; Mono; Animal adulto; Macho</SD>
<LO>INIST-20953.354000077139450030</LO>
<ID>98-0354366</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002F65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:98-0354366 |texte= Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys }}
This area was generated with Dilib version V0.6.23. |